% | $
Quotes you view appear here for quick access.

Rexahn Pharmaceuticals, Inc. Message Board

  • eurotyle eurotyle Jan 9, 2014 7:57 PM Flag

    Honestly...Does the short interest even matter?

    It's a mere 4 million shares. This can be covered easily within an hour on a day like today.

    Show me another biotech (like GALE) that had a monster short interest and the shorts got rolled over.

    RNN might be for real with their clinicals and technologies, worst case (if it fails) they tried to cure/slow down the worst disease out there.

    Either way, works/fails - We should be surely priced higher (My guess is $1.25- $1.50) in anticipation of that "hope" factor. I wouldn't go bonkers quite yet and run this to $3 which the Roth Capital analyst said...Maybe in due time. Analyst time-frames are usually until year end or 18/months.

    Sentiment: Hold

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • it would be illogical to short rnn or any penny stock for that matter. success or no, rnn's potential is enough to make a bullish case. i'm not rooting for a drop in share prices, but would certainly like to buy some on the dips, if possible. one things for certain, the bull has been let loose on rnn. any shorter could get trampled easily. it's time to be the bull and ride her, but a word of caution, she's a bull and there are swings from her kicking legs and horns. long rnn. take us to pluto and then to alpha centauri please.

    • Shorts are a misdirected anger obsession with some longs. Short interest is 2.7 days to cover, enough for a bump, but short squeezes of that magnitude have little lasting effect. What we needed was big boy buying and that's happening now-Bigtime. Who cares about a few shorts? Institutional buying is the key. And, of course, success with the pipeline.

      Sentiment: Strong Buy

      • 2 Replies to attymdmnola
      • With 20 million volume traded on the same day of an analyst upgrade and a few liver-biotech plays (GALT, ICPT, CNAP) broke out....this news definitely does not deserve 20/million shares to be traded.

        Something is up or someone clipping the mom and pops shares (100, 500, 1000, 2000, etc) and locking them up for a long-term upward move.

        If she goes up a dime or if she drops a dime, no big deal. Sure it might look like a 12-15% swing, but companies that are this cheap...they will swing like this pretty much weekly.

      • Shorting a biotech trading south of $1.00, unless it failed superbly (like Affymax - AFFY) is simply suicidal.

        What if we had positive phase 2 results pre-market that were blockbuster, this thing would open around $4-$5 and shorts would be upside down like 600% barely in time for morning coffee.

        People that short baby biotechs are simply insane, especially in a sector that's been white hot for nearly two years....and the bull is still running wild.

        Sentiment: Hold

0.2599+0.0038(+1.48%)Jul 28 4:00 PMEDT